

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

NCT05664126

Status	RECRUITING
Phase	Phase 2
Sponsor	St. Jude Children's Research Hospital
Enrollment	42 participants

Key Eligibility Criteria

Inclusion (21)

- Patients who have undergone haploidentical HCT or a matched-sibling/matched-unrelated donor HCT, and have CMV and/or ADV detected by PCR in the peripheral blood refractory to antiviral therapy per institutional BMTCT SOP 20.05.
 - Definition of "refractory" viremia is persistent positive CMV or ADV viremia after 14 days of treatment per institutional SOP, or an increasing copy number (e1 log) after 7 days of treatment.
 - Patients have no suspected or confirmed GVHD.
 - Availability of haploidentical donor for isolation of virus-specific T-cells.
 - Have not received a Donor Lymphocyte Infusion in the past 4 weeks.
- ... and 16 more (see full listing online)

Exclusion (7)

- Active GVHD.
 - Pregnancy.
 - Inability to provide consent.
 - Need for vasopressor or ventilatory support Patients receiving steroids >0.5 mg/kg prednisone equivalent at the time of VST infusion
 - Donor Lymphocyte Infusion within 4 weeks prior to VST infusion.
- ... and 2 more (see full listing online)

Locations (1 total)

St. Jude Children's Research Hospital, Memphis, Tennessee, United States